Preferential Treatment: US FDA Asks Patients For Their Input
Executive Summary
As the agency continues to incorporate more patient-preference data into its regulatory process, it is asking stakeholders on the kinds of diseases and other factors it should consider when evaluating patient-preference information. The feedback is ultimately meant to inform regulators and sponsors about what patients want as they develop products.
You may also be interested in...
Journal Article Gives Insight On Using Personal Preference Information In Clinical Trials
The FDA has expressed interest in using patient preference information (PPI) to make regulatory decisions for medical devices. A recent article gives recommendations to medical device sponsors who want to study PPI in clinical trials.
Lifting The Hood On MDUFA V
The document includes promises from the US FDA related to review timelines, consensus standards, the Total Product Life Cycle pilot, and more.
Shuren: New Uncertainty Draft Guidance Looks Beyond p-Values
After years of talking about how to tackle uncertainty of benefit/risk in devices under review, US FDA has released a guidance on the issue. Medtech Insight caught up with FDA device center director Jeff Shuren at a meeting in Washington, DC, to talk about the guidance and what he hopes will come of it.